List view / Grid view
22 September 2014 | By Children’s Cancer Institute and Abcam plc
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development...
16 September 2014 | By Andrew Lloyd & Associates
Curie-Cancer and Inventiva announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR...
15 September 2014 | By The Institute of Cancer Research, London
Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease...
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
2 July 2014 | By Roche
Roche announced that Genentech has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California, USA...
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
18 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
29 May 2014 | By SMI Group
Companies are realizing that their own internal R&D groups alone are not enough and as pharma groups slash their internal R&D projects...
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
8 April 2014 | By OncoEthix
OncoEthix announced that the interim results from its ongoing Phase I clinical trial of OTX015, in patients with hematologic malignancies, were presented at the annual American Association of Cancer Research...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
12 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
